This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Medicinal cannabis inquiry: written evidence

Published: 08 Feb 2019 in

In December 2018, the House of Commons Health and Social Care Committee launched an inquiry on the usage of medicinal cannabis products as the first part of a wider inquiry into the impact of drugs policy on public health.

In our response, the Society raised a number of concerns regarding the usage of ‘Cannabis plant-derived medicinal products’ (CDMPs) in medicine and research. We called for a formal process for reviewing scheduling decisions using current scientific evidence. Specifically, we recommended rapid consideration of whether Epidiolex should be granted UK authorisation.

Read our response.